Most Read Articles
Roshini Claire Anthony, Yesterday

Many pregnant women may not be getting adequate nutrition as advised by dietary guidelines, researchers of an Australian study found.

6 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
4 days ago
Misoprostol promotes the healing of small bowel ulcers in aspirin users whose condition is complicated by small bowel bleeding, reports a recent trial.
Jairia Dela Cruz, 5 days ago
An adjuvant trastuzumab treatment course shortened to 9 weeks has failed to demonstrate noninferiority to the standard 1-year course in terms of disease-free survival in breast cancer patients, although the shortened course confers benefits for the risk of severe cardiac toxicity, according to the results of the phase III randomized Short-HER study.

Product Highlight-Victoza

27 Sep 2018
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk

Victoza is now approved in Malaysia for prevention of
cardiovascular events.1

• The only GLP-1 proven to prevent CV events – 22% relative risk reduction in CV death2
• Unsurpassed HbA1c efficacy across 14 head-to-head trials3-6
• Unsurpassed weight loss across 14 head-to-head trials3-6


References:
1. Victoza Malaysia Prescribing Information.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2016;375(4):311-322.
3. Pratley R, Nauck M, Bailey T, et al; for the 1860-LIRA-DPP4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes; a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397-407.
4. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial. Diabetes Care. 2016;39(9):1501-1509.
5. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;38(9861):117-124.
6. References on file.

Further information is available in section 11b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

Many pregnant women may not be getting adequate nutrition as advised by dietary guidelines, researchers of an Australian study found.

6 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
4 days ago
Misoprostol promotes the healing of small bowel ulcers in aspirin users whose condition is complicated by small bowel bleeding, reports a recent trial.
Jairia Dela Cruz, 5 days ago
An adjuvant trastuzumab treatment course shortened to 9 weeks has failed to demonstrate noninferiority to the standard 1-year course in terms of disease-free survival in breast cancer patients, although the shortened course confers benefits for the risk of severe cardiac toxicity, according to the results of the phase III randomized Short-HER study.